Slide 1: Developing Selective Oral DHODH Inhibitor IMU-838 as COVID-19 Treatment
| , Immunic Therapeutics Developing Selective Oral DHODH Inhibitor IMU-838 as COVID- LS HReleOy April 22; 2020."
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements + Certain statements contained inthis presentation regarding matters that are not historical facts are forward-loaking statements withinthe meaning of Section 216 of the Securities and Exchange Act of 1934, as amended, andthe Private Securities Li
Slide 3: Developing new class of oral therapies for inflammatory and autoimmune diseases
e developing new a (5) = n-class or the treatment nflammatory and autoimmune diseases. £) Immunic enamine — eacReNEM
Slide 4: COVID-19: The Therapeutic Challenge
COVID-19: The Therapeutic Challenge Stage! Stage ll Stage Ill (Early Infection) (Pulmonary Phase) (Hyperinflammation Phase) ' en re) 1 1 Viral response phase Severity of IlIness tness of Breath 300mmi i symptoms Glnica signs COMID-19 IlIness in Native and Immunosuppressed States: A Clinical Therapeu
Slide 5: Development Pipeline
Development Pipeline Pres Phase 1 Phase 2 Phase 3 IMU-838 Multiple Sclerosis DHODH | Ulcerative Colitis. DHODH | EEE Crohn’s Disease DHODH Investigator-Sponsored Trial performed at Mayo Clinic/ NIH PSC DHODH Ee COVID-19 DHODH a >_— o> *_o> — a IMU-935 Psoriasis RoRyt Orphan Al : RORyt Diseases ¥ IMU
Slide 6: Potential Treatment Option for COVID-19
IMU-838: Potential Treatment Option for COVID-19 * IMU-838 is an orally available DHODH inhibitor with both, antiviral and anti-inflammatory effects * Advanced clinical drug candidate with attractive pharmacokinetic, safety and tolerability profile with more than 650 individuals exposed to date * Ho
Slide 7: Activity Against SARS-CoV-2 and Other Viruses
IMU-838: Activity Against SARS-CoV-2 and Other Viruses IMU-838 ney: ¢ IMU-838 is active against SARS-CoV-2 ¢ IMU-838 has shown broad-spectrum antiviral activity against different pathogenic viruses with EC... values in single digit WM range Arenavirus SARS-CoV-2 HIV & Immunic Immunic, Ine 22.08.2020
Slide 8: Small Molecule DHODH Inhibitor
IMU-838: Small Molecule DHODH Inhibitor DHODH Inhibitors: Active Against SARS-CoV-2! Uninfected Virus Normal Cell Infected Cell Insufficient pyrimidine recycling Virus infection silent * Pyrimidine de novo * DHODHnot synthesis activated important * DHODH4 Block of Pyrimidine de novo Synthesis IMU-83
Slide 9: Advanced Clinical Drug Candidate
IMU-838: Advanced Clinical Drug Candidate * Three phase 2 trials ongoing * Multiple sclerosis — phase 2 with 210 patients — fully recruited * Ulcerative colitis — phase 2 with 240 patients — ongoing * Primary sclerosing cholangitis — 30 patients, IST — ongoing * Well tested safety: 650 individuals e
Slide 10: Potential Phase 2 Clinical Trial Design in COVID-19
IMU-838: Potential Phase 2 Clinical Trial Design in COVID-19 * Immunic intends to initiate a prospective, multicenter, randomized, placebo-controlled, double-blind phase 2 clinical trial in patients with moderate COVID-19 disease and clinical symptoms ¢ Adequate drug supply exists to begin clinical
Slide 11: Questions?
Questions? Thank you for listening! We are happy to answer your questions through the question and answer tool Immunic, Inc. 1200 Ave of the Americas, Suite 200 New York, NY 10036 USA & Immunic Jessica Breu Manager IR & Communications Phone: +49 89 2080 477 09 Email: ir@imux.com © Immunic, Inc 22.04
Slide 12: ‘i AustraliaMelbourne
‘i AustraliaMelbourne smal est-in- ann selectivel B D Ow ug inhibitors ¢) OE roraTS reclinical. Qos DOD: GE o RORVtS SS. Etre yce: NASD NOSE QO 2s 23892 bowasbiotec =e — Eta? Bx s £26 ImMuUNICEe == “2823 Cohealthcare oF 33 “2s immunology = s'ye= moleculéae> | oe s§ sclerosis z DHODHIMU- 935PSC_ E in